MedTrace Logo

DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM

NCT07377435 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-05-08

No results posted yet for this study

Summary

This study is to evaluate the safety and effectiveness of dendritic cell DC/MM fusion vaccine in combination with standard of care B-cell maturation antigen (BCMA) CAR-T cell therapy in participants with relapsed/refractory multiple myeloma.

The names of the study drugs involved in this study are:

* DC/MM fusion vaccine (a type of personalized cancer vaccine)
* Granulocyte-macrophage colony-stimulating factor (GM-CSF) (a type of growth factor or hormone)

Conditions

Interventions

BIOLOGICAL

DC/MM Fusion Vaccine

Dendritic Cell and tumor fusion vaccine, via subcutaneous injection (under the skin), per protocol.

DRUG

GM-CSF

Granulocyte-Macrophage Colony-Stimulating Factor, via subcutaneous injection, per standard of care.

Sponsors & Collaborators

  • The V Foundation

    collaborator OTHER

  • David Avigan

    lead OTHER

Principal Investigators

  • Jacalyn Rosenblatt, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-30
Primary Completion
2028-03-01
Completion
2032-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07377435 on ClinicalTrials.gov